C4-carbonothioate-substituted tryptamine derivatives and methods of using

EP4493542A4Pending Publication Date: 2026-03-04ENVERIC BIOSCIENCES CANADA INC
View PDF -1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2022-08-22
Publication Date
2026-03-04

AI Technical Summary

Technical Problem

Tryptamine-based drugs often exhibit suboptimal pharmacological effects due to non-specific molecular interactions with receptors, broad bodily distribution leading to undesirable side effects, and rapid blood plasma clearance, necessitating more frequent dosing and affecting patient compliance.

Method used

Development of C4-carbonothioate-substituted tryptamine derivatives with specific chemical formulas that interact with 5-HT receptors and other transmembrane transport proteins, potentially modulating their activity and providing improved pharmacokinetic and pharmacodynamic profiles.

Benefits of technology

The C4-carbonothioate-substituted tryptamine derivatives demonstrate enhanced specificity and prolonged action, reducing side effects and improving therapeutic efficacy by targeting specific receptors and transport proteins, potentially leading to more effective and convenient dosing regimens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
Need to check novelty before this filing date? Find Prior Art